Financial Data and Key Metrics Changes - The company reported net sales of $375 million for Q2 2025, reflecting a 7.6% increase year-over-year [27] - Adjusted EBITDA margin improved to 13.1%, marking the highest level in nearly two years [6][30] - Gross margin decreased to 31.2% from 31.8% year-over-year, while adjusted gross margin was 31.3% compared to 31.9% in the prior year [27][28] Business Line Data and Key Metrics Changes - In the Powered Vehicles Group (PVG), net sales increased by $4.9 million to $123.5 million, driven by growth in the motorized two-wheel business [11] - The Aftermarket Applications Group (AAG) saw net sales rise 6.5% to $114.1 million, attributed to increased demand for aftermarket products [14] - The Specialty Sports Group (SSG) reported an 11% increase in net sales to $137.2 million, supported by strong bike business performance [18] Market Data and Key Metrics Changes - The company noted that the consumer discretionary environment is stabilizing, which is expected to support enhanced profitability [10] - Tariff impacts were highlighted, with an increase in expected tariff costs from $38 million to $50 million for the year, affecting various segments [33][49] Company Strategy and Development Direction - The company is focused on four key initiatives: footprint consolidation, portfolio optimization, working capital management, and a $25 million cost reduction program [7][9] - Emphasis on product innovation and R&D is seen as crucial for maintaining market share and driving long-term growth [6][10] - The company is strategically expanding into new OEMs and industries, particularly in the motorcycle and electric vehicle sectors [11][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macro challenges and achieve growth through operational excellence and innovation [10][35] - The outlook for the second half of 2025 remains positive, with expectations for improved order books and product launches [25][32] - Management acknowledged ongoing tariff pressures but emphasized efforts to mitigate these impacts through various strategies [33][87] Other Important Information - The company is on track to reduce net leverage to below three times by year-end, with a focus on debt reduction [31] - Free cash flow generation is anticipated to be approximately $80 million for the full year [32] Q&A Session Summary Question: What is driving the raised sales guidance? - Management indicated that the entire enterprise is performing well, leading to increased confidence in the second half of the year [41][42] Question: How is the company addressing the higher tariff impact? - The increase in tariff impact is attributed to both the Marucci mix and products from Taiwan, with specific allocations provided for each segment [49] Question: Is there directional improvement in the powersports market? - Management noted that while stability is returning to the powersports market, interest rate improvements are necessary for significant growth [50] Question: What is the outlook for the bike business? - The bike business is expected to grow, with a focus on stabilizing inventory levels and preparing for new product launches [63][67] Question: What are the growth vectors for Marucci? - Management highlighted global growth, diversification in product lines, and expansion into softball as key growth areas for Marucci [78][81]

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $100.3 million, a 17% increase compared to Q4 2023, driven primarily by dispensary revenue [21] - Full year 2024 revenue reached $393 million, representing a 21.3% increase from 2023 [25] - Gross profit for Q4 2024 was $14.6 million, a 2% increase year-over-year, while full year gross profit was $54 million, a 9.4% decrease from 2023 [22][25] - Net loss for Q4 2024 was $13 million, an improvement of $5.6 million compared to Q4 2023, while the full year net loss was $64.6 million, a decrease of $18.4 million from 2023 [23][27] - Adjusted EBITDA for Q4 2024 was negative $7.8 million, compared to negative $6.3 million in Q4 2023, and for the full year, it was negative $35.7 million [23][27] Business Line Data and Key Metrics Changes - Value-based patient services saw significant growth with six new contracts totaling over 270,000 lives launched in Q3 and Q4 2024 [9] - Pharmacy and medically integrated dispensaries generated $48 million in Q4 and $180 million for the full year, reflecting a 73% annualized growth [10] - SG&A expenses decreased by 12% in Q4 2024 compared to Q4 2023, demonstrating operational efficiency [12] Market Data and Key Metrics Changes - The company expanded its operations outside California, signing two new contracts in Florida during Q4 2024, totaling over 200,000 lives [9] - The company is positioned to handle substantial growth in new markets without increasing overhead costs [31] Company Strategy and Development Direction - The company aims to achieve profitability and positive cash flow by the end of 2025, focusing on operational management and strategic market expansion [8][39] - A key strategy includes optimizing the cost structure and enhancing financial flexibility through debt restructuring and capital raises [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in crossing the line to profitability by the end of 2025, despite 2024 not meeting expectations [8] - The company anticipates a gradual reduction in losses throughout 2025, with expectations of positive EBITDA in Q4 [35] Other Important Information - Cash and cash equivalents increased to $49.7 million by the end of Q4 2024, aided by working capital management [28] - The company successfully amended its facility agreement, including a $20 million principal paydown of outstanding debt [16] Q&A Session Summary Question: What are the significant moving factors for 2025 guidance? - Growth in capitation contracts and organic growth in fee-for-service and dispensary are essential for achieving targets [45] Question: Will patient service be a meaningful growth driver in 2025? - Yes, the capitation segment will be the primary driver of overall profitability [48] Question: What is the capacity of new clinics in Florida compared to California? - California clinics are operating at about 75% capacity, while Florida clinics are at approximately 40% capacity [54] Question: Any thoughts on the recent reimbursement landscape? - General macro trends in the oncology industry are favorable, with potential benefits from changes related to drug pricing [59]

Financial Data and Key Metrics Changes - For Q4 2024, total revenue was $702.8 million, flat compared to Q4 2023, while full year revenue reached $2.79 billion, a slight increase of just over 1% [61][63] - Adjusted EBITDA for Q4 was $40.4 million, totaling $161.1 million for the full year, reflecting a decrease of approximately 20% [11][62] - Consolidated net loss for Q4 was $23.5 million, while adjusted net income was $2.7 million, or $0.19 per share [63] Business Line Data and Key Metrics Changes - The NEMT segment, representing 70% of total revenue, generated $495 million in revenue, remaining flat year over year [64] - Personal Care Services (PCS) revenue increased by 3% year over year to $186.6 million, driven by a 3.5% growth in revenue per hour [68] - Remote Patient Monitoring (RPM) revenue was $19.2 million, representing 3% of total revenue but 16% of adjusted EBITDA [69] Market Data and Key Metrics Changes - Average monthly members in the NEMT segment decreased by approximately 11% year over year, while trip volume increased by 8.5% compared to a year ago [64] - The total addressable market for NEMT is estimated to exceed $6 billion, with an annual MCO revenue base of $1 billion entering 2025 [31] Company Strategy and Development Direction - The company aims to strengthen technology-enabled platforms across NEMT, personal care, and monitoring while executing strategic financial initiatives and divesting platforms [12][22] - A focus on monetizing select segments and unlocking value is emphasized, with a strategic alternatives committee established to oversee the divestiture process [22][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the unprecedented challenges faced in 2024, including Medicaid redetermination and increased healthcare utilization, but expressed confidence in navigating these disruptions [8][9] - The company is optimistic about future growth opportunities, particularly in the MCO segment, with a win rate exceeding 90% over the past two years [31] Other Important Information - The company secured an incremental $75 million term loan and $30 million in new second lien notes to enhance financial flexibility [14][60] - New board appointments were made to enhance expertise in operational efficiency and technology innovation [15][20] Q&A Session Summary Question: How does ModivCare Inc.'s exposure to Medicaid affect fee-for-service contracts? - Management expects that any Medicaid cuts will primarily affect healthier members, and they are currently negotiating to reset payments based on member mix [78][80] Question: Can you provide an update on the sale process? - Management indicated that discussions are ongoing and they are encouraged by the interest in their platforms, but specific timing for sales was not disclosed [83][84] Question: What is the current membership status in NEMT and monitoring? - Membership in NEMT has decreased significantly, with expectations of recovery as new contracts are pursued [89][90] Question: What are the expectations for cash flow in 2025? - Management confirmed that they expect a return to positive free cash flow in the latter half of 2025, with improvements in contract structures aiding liquidity [112][117] Question: How will the transition from shared risk to fee-for-service contracts impact revenue? - Approximately 25% of revenue is expected to shift to fee-for-service contracts, which will help stabilize cash flow and reduce working capital shifts [124][126]